Innova Medical Group Acquires Calif.-Based MPS Medical Inc. Significantly Expanding COVID-19 Rapid Test Manufacturing Capacity in the US

“We are excited to be part of the fast-growing Innova Medical family and to participate directly in helping the people in the US and other countries to better combat the COVID-19 pandemic,” said Barry Kazemi, CEO of MPS Medical Inc.

Innova Medical Group, Inc. (IMG), the world’s largest manufacturer of rapid antigen test kits and a leading supplier of COVID-19 testing solutions globally, acquired California-based MPS Medical, Inc, significantly expanding IMG’s COVID-19 rapid antigen test kit manufacturing capacity in the USA.

MPS Medical, Inc is an FDA registered medical device manufacturer that has been producing high-quality medical devices for domestic and international customers since 2014. MPS Medical’s ISO 13485 certified, GMP compliant facility has an initial production capacity of more than 700,000 SARS-CoV-2 antigen rapid test kits per shift, immediately increasing Innova’s global production capacity of the rapid antigen test kits to nearly 9 million units a day. Under the new ownership by Innova Medical Group Inc., MPS Medical Inc. plans to aggressively ramp up its capacity to multi-millions of units per day in California, anticipating robust demand for Innova’s SARS-COV-2 rapid qualitative test kits in the USA and globally.

“We are excited to be part of the fast-growing Innova Medical family and to participate directly in helping the people in the US and other countries to better combat the COVID-19 pandemic,” said Barry Kazemi, CEO of MPS Medical Inc.

“The acquisition of California-based MPS Medical is a testament of our commitment to making top-quality products locally in the US for domestic and international markets,” said Daniel Elliott, President, and CEO of Innova Medical Group, Inc. while welcoming MPS Medical employees to the company. “With Innova’s deep expertise in COVID testing and business strategy, MPS Medical will continue to excel as a manufacturer of not only our best-in-class antigen test kits for COVID-19 but also other innovative medical products post-pandemic.”

As the largest supplier globally for rapid COVID testing, Innova has delivered more than 220 million COVID-19 test kits to over 20 countries in Q4 2020, including the United Kingdom, where Innova tests are used as a COVID screening tool. Innova Medical is under contract to deliver millions of additional test kits globally in Q1 2021, some of which will come from the MPS Medical production site.

As a leading COVID testing solution provider, Innova recently acquired California-based Biological Laboratory Inc., a CLIA-certified clinical laboratory with more than 130 employees providing COVID testing services in Los Angeles County, California. In addition, Innova partners with Ashfield Healthcare to provide consulting and implementation services to governments and corporations. Innova is also deploying the QMC HealthID™ App that enables patients and organizations to track and report their COVID test status in a secure and contact-less way.

About MPS Medical Inc.

MPS Medical, Inc. develops and manufactures medical devices to advance healthcare across multiple areas of care. Its 30-year history began in 1990 as MPS Acacia. MPS Medical began manufacture of MPS Acacia’s market-leading neonatal intensive care products in 2014 and has since expanded into multiple successful divisions. These include infusion therapy, cell therapy manufacturing, sterile compounding and in-home pharmacy, as well as OEM services. Its custom manufacturing capabilities enable clinical professionals to create new products to meet the specific needs of their patients. MPS Medical, Inc. maintains Class 7 cleanrooms for production in its Brea, California facilities.

About Innova Medical Group Inc.

Innova Medical Group, Inc. (IMG) delivers better global health outcomes with its deep expertise in testing and unique offerings in diagnostic medical devices and services that help tackle some of the world’s most challenging healthcare problems. IMG specializes in innovative screening, testing, and diagnostics for cancer, heart disease, arterial calcification, stroke, and virus detection focused on infectious diseases. In response to the global pandemic, IMG developed an end-to-end ecosystem of rapid diagnostic and screening tests, along with digital reporting and tracing applications to help organizations manage the COVID-19 crisis.

For more information on Innova Medical Group’s COVID-19 ecosystem or to order COVID-19 rapid diagnostic tests, contact

Media Inquiries, contact


Share article on social media or email:

Leave a Reply